James W.F. Catto

Active 2001–2025

Also published as
James W F Catto
155
Papers
29,922
Citations
84
h-index
151
i10-index

Citations

Citations per year for James W.F. Catto1991: 1 citations2001: 2 citations2002: 2 citations2003: 5 citations2004: 3 citations2005: 19 citations2006: 34 citations2007: 32 citations2008: 42 citations2009: 36 citations2010: 53 citations2011: 72 citations2012: 104 citations2013: 147 citations2014: 115 citations2015: 161 citations2016: 187 citations2017: 201 citations2018: 279 citations2019: 1,106 citations2020: 1,405 citations2021: 1,168 citations2022: 893 citations2023: 640 citations2024: 1,212 citations2025: 557 citations2026: 32 citations1992–2000: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,488 citing papers, 19.2% of this breakdownChina: 1,395 citing papers, 10.8% of this breakdownUnited Kingdom: 976 citing papers, 7.5% of this breakdownItaly: 892 citing papers, 6.9% of this breakdownGermany: 697 citing papers, 5.4% of this breakdownCanada: 556 citing papers, 4.3% of this breakdownNetherlands: 549 citing papers, 4.2% of this breakdownFrance: 519 citing papers, 4% of this breakdownSpain: 403 citing papers, 3.1% of this breakdownJapan: 325 citing papers, 2.5% of this breakdownAustralia: 317 citing papers, 2.4% of this breakdownSwitzerland: 296 citing papers, 2.3% of this breakdown
0%19.2%Other 27.4%

Fields

  • Medicine70.1%
  • Biochemistry, Genetics and Molecular Biology22.5%
  • Engineering1%
  • Immunology and Microbiology1%
  • Computer Science1%
  • Health Professions0.8%
  • Other3.6%

Topics

  • Bladder and Urothelial Cancer Treatments12.4%
  • Prostate Cancer Diagnosis and Treatment8.2%
  • Prostate Cancer Treatment and Research6.2%
  • Urinary and Genital Oncology Studies5.7%
  • MicroRNA in disease regulation2.8%
  • Epigenetics and DNA Methylation2.6%
  • Other62.1%

Coauthors

All papers

Open in search
  1. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Susan Bullman, Kristen Leraas, Tara M. Lichtenberg, Catherine J. Wu, N. Schultz, Gad Getz, Matthew Meyerson, Gordon B. Mills, David J. McConkey, Rehan Akbani, Hikmat Al‐Ahmadie, Monique Albert, Iakovina Alexopoulou, Adrian Ally, Tatjana Antic, Manju Aron, Miruna Balasundaram, John M.S. Bartlett, Stephen B. Baylin, Allison Beaver, Joaquim Bellmunt, İnanç Birol, Lori Boice, Moiz S. Bootwalla, Jay Bowen, Reanne Bowlby, Denise Brooks, Bradley M. Broom, Wiam Bshara, Susan Bullman, Eric Burks, Flavio Mavignier Cárcano, Rebecca Carlsen, Benilton S. Carvalho, André Lopes Carvalho, Eric Castle, Mauro A. A. Castro, Patricia Castro, James W.F. Catto, Vinicius S Chagas, Andrew D. Cherniack, David Chesla, Caleb Choo, Eric Chuah, Sudha Chudamani, Victoria K. Cortessis, Sandra Cottingham, Daniel Crain, Erin Curley, Bogdan Czerniak, Siamak Daneshmand, John A. Demchok, Noreen Dhalla, Hooman Djaladat, John Eckman, Sophie Egea, Jay Engel, Ina Felau, Martin L. Ferguson, Johanna Gardner, Julie M. Gastier‐Foster, Mark Gerken, Gad Getz, Ewan A. Gibb, Carmen Gomez‐Fernandez, Dmitry A. Gordenin, Guangwu Guo, Donna E. Hansel, Jodi Harr, Arndt Hartmann and 113 more - Cell 2017 cited by 2,535

  2. Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 cited by 751

  3. Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors

    Authors: , , , , , , , , , , , , , , , , - European Urology 2023 cited by 481

  4. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2016 cited by 2,650

  5. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System)

    Authors: , , , , , , , , , , , , , , , , , - European Urology 2018 cited by 636

  6. Epidemiology and Risk Factors of Urothelial Bladder Cancer

    Authors: , , , , , , , , , , - European Urology 2012 cited by 2,187

  7. Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018

    Authors: , , , , , , , , , , , - European Urology 2018 cited by 840

  8. Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in the Detection of Clinically Significant Prostate Cancer in the Prostate Imaging Reporting and Data System Era: A Systematic Review and Meta-analysis

    Authors: , , , , , , , , , , , , , , , , , , - European Urology 2020 cited by 339

  9. Systematic Review of Complications of Prostate Biopsy

    Authors: , , , , , , , , - European Urology 2013 cited by 1,057

  10. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 cited by 322

  11. Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , iROC Study Team, E Ruth Groves, Louise Goodwin, Jayne Willson, Phillip Ravencroft, Stephen Kennish, Derek J. Rosario, Carol Torrington, Rajesh Nair, Ramesh Thurairaja, Sue Amery, Kathryn Chatterton, Samantha Broadhead, David F. Hendry, Abdullah Zreik, Sunjay Jain, S M Prescott, Hannah Roberts, Angela Morgan, Chris J. Main, Elspeth Bedford, Lorraine Wiseman, Bernice Mpofu, Claire Daisey, Michelle Donachie, Jon Aning, Lyndsey Johnson, Carol Brain, Constance Shiridzinomwa, Martin Ebon, Alexander Hampson, Roisin Schimmel, Scott W. Horsley, Sayyida Nembhard, Clare E. Collins, Jemma Gilmore, Faith Wilson, Louise Peacock, Sheena Lim, Rhosyll Gabriel, Rachael Sarpong, Melanie Tan - JAMA 2022 cited by 320

  12. Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philip A. Powell, Stephen M. Prescott, Derek J. Rosario, Edward Rowe, Michael J. Davis, Emma L. Turner, Richard M. Martin, David E. Neal - New England Journal of Medicine 2016 cited by 1,328

  13. Repeat Transurethral Resection in Non–muscle-invasive Bladder Cancer: A Systematic Review

    Authors: , , , , , , , , - European Urology 2018 cited by 332

  14. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2020 cited by 527

  15. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021

    Authors: , , , , , , , - European Urology 2021 cited by 220

  16. The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks

    Authors: , , , - European Urology 2015 cited by 448

  17. Changes in circulating microRNA levels associated with prostate cancer

    Authors: , , , , , , , , - British Journal of Cancer 2012 cited by 712

  18. Quality of Life After Bladder Cancer: A Cross-sectional Survey of Patient-reported Outcomes

    Authors: , , , , , , , , , , , - European Urology 2021 cited by 163

  19. Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit

    Authors: , , , , , , , , , - BMJ 2023 cited by 86

  20. Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Dingwei Ye, Martin Boegemann, Florian Roghmann, Albert Heidrich, Eva Hellmis, Óscar Rodriguez Faba, José Luís Domínguez‐García, Romain Mathiéu, Marc Colombel, Franck Bladou, Xavier Artignan, Nikhil Vasdev, Rajendra Shimpi, Valentina Guadalupi, Rosa Tambaro, Zuzana Sirotovà, Massimiliano Spada, Andrea Necchi, Hiroomi Nakatsu, Eiji Kikuchi, Nobuaki Shimizu, Kent Kanao, Makoto Sumitomo, Yushi Naito, Won Sik Ham, Seung-Il Jung, H.K. Ha, Kwan Joong Joo, Ja Hyeon Ku, Ho Kyung Seo, Seok Joong Yun, Anna Kołodziej, Janusz Ławiński, David Morris, Siamak Daneshmand, Badar M. Mian, Eugene Lee - Annals of Oncology 2023 cited by 78

  21. Prospective Assessment of Vesical Imaging Reporting and Data System (VI-RADS) and Its Clinical Impact on the Management of High-risk Non–muscle-invasive Bladder Cancer Patients Candidate for Repeated Transurethral Resection

    Authors: , , , , , , , , , , , - European Urology 2019 cited by 210

  22. Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jon Oxley, John Staffurth, Richard J. Bryant, David E. Neal - NEJM Evidence 2023 cited by 96

  23. Radical Cystectomy Against Intravesical BCG for High-Risk High-Grade Nonmuscle Invasive Bladder Cancer: Results From the Randomized Controlled BRAVO-Feasibility Study

    Authors: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 120

  24. Reduced Expression of miRNA-27a Modulates Cisplatin Resistance in Bladder Cancer by Targeting the Cystine/Glutamate Exchanger SLC7A11

    Authors: , , , , , , - Clinical Cancer Research 2014 cited by 226